Global Blood Therapeutics (GBT) Financials

$68.49

$0.00 (0.00%)

As on 05-Oct-2022 09:30EDT

Market cap

$4,621 Mln

Revenue (TTM)

$235 Mln

P/E Ratio

--

P/B Ratio

39

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	234.86	194.75	123.80	2.11	--	--
Cost of Revenue	4.45	3.32	1.99	0.05	--	--
Gross Profit	230.41	191.43	121.82	2.06	--	--
Operating Expenses	529.65	479.12	365.97	291.64	182.74	119.25
Operating Profit (EBIT)	-299.24	-287.69	-243.17	-281.28	-182.74	-119.25
Other Income	-22.38	-14.92	-4.38	--	--	--
Profit before Tax	-321.62	-302.61	-247.55	-266.77	-174.19	-117.02
Provision for Tax	0.84	0.48	--	0.00	--	--
Profit after Tax (Net Income)	-322.46	-303.09	-247.55	-266.77	-174.19	-117.02
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-322.46	-303.09	-247.55	-266.77	-174.19	-117.02

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	118.36	196.41	416.16	578.69	572.80	318.80
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	658.99	654.80	228.81	145.95	11.07	11.65
Current Liabilities	93.09	88.00	79.03	71.45	33.77	26.26
Total Liabilities	963.53	939.21	724.00	796.10	617.64	356.72

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	230.43	137.24	91.84	168.10	131.86	32.41
Current Assets	640.01	801.97	632.16	628.00	485.78	324.31
Total Assets	963.53	939.21	724.00	796.10	617.64	356.72
Total Debt*	658.39	659.62	153.65	75.43	--	--
Net Current Assets	546.92	713.97	553.13	556.54	452.01	298.05

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-256.81	-211.86	-194.42	-135.38	-93.02
Cash Flow from Investing Activities	--	12.11	317.31	-76.86	-184.16	-35.00
Cash from Financing Activities	--	434.34	87.12	298.16	397.91	235.19
Net Cash Inflow / Outflow	--	189.63	192.57	26.88	78.37	106.26

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	-5.02	-4.81	-4.06	-4.60	-3.42	-2.79
Cash EPS ($)	--	-4.67	-3.88	-4.43	-3.33	-2.75
Adjusted Book Value ($)	--	3.12	6.82	9.98	11.23	7.59
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-4.08	-3.47	-3.35	-2.65	-2.21
Free Cash Flow per Share ($)	--	-4.13	-3.62	-3.41	-2.75	-2.29

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-42.51	-40.45	-43.49	-39.07	-46.34
ROE (%)	-204.89	-98.96	-49.77	-46.33	-39.07	-46.34
ROA (%)	-39.06	-36.45	-32.57	-37.74	-35.76	-41.86
EBIT Margin (%)	-126.62	-147.44	-192.03	-12,654.93	--	--
Net Margin (%)	-151.76	-168.55	-207.29	-12,654.93	--	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	42.53	0.57	57.73	--	--	--
EBIT Growth (%)	-17.25	-20.78	10.88	-45.98	-53.25	-43.45
Net Profit Growth (%)	-21.13	-22.43	7.20	-53.14	-48.85	-41.90
EPS Growth (%)	-16.45	-0.19	0.12	-0.35	-0.23	-0.11
Book Value Growth (%)	-64.79	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	-6.08	-10.67	-17.28	-12.02	-14.12
Price / Book Value	39.05	9.39	6.35	7.97	3.65	5.18
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-16.53	-6.53	-9.85	-15.87	-9.07	-11.38
Close Price ($)	31.95	29.27	43.31	79.49	41.05	39.35
High Price ($)	40.69	52.49	87.54	82.93	68.05	45.85
Low Price ($)	21.65	24.61	36.49	39.53	30.15	13.60
Market Cap ($ Cr)	4,621.44	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	4.92	3.36	0.37	0.13	--	--
Short term debt to equity ratio	0.05	0.03	0.01	0.00	--	--
Current Ratio	6.88	9.11	8.00	8.79	14.38	12.35
Quick Ratio	6.17	8.45	7.49	8.77	--	12.35
Interest Coverage	-12.02	-18.57	-24.24	--	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	12.67	14.79	14.14	125.09	--	--
Asset Turnover	0.28	0.23	0.16	0.00	--	--
Receivable days	--	43.42	29.70	456.91	--	--
Inventory Days	--	5,420.65	3,816.18	9,717.17	--	--
Payable days	--	1,882.15	2,731.01	63,412.73	--	--
Cash Conversion Cycle	--	3,581.91	1,114.88	-53,238.65	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.